Sedashkina Olga Aleksandrovna (RU),Седашкина Ольга Александровна (RU),Makovetskaya Galina Andreevna (RU),Маковецкая Галина Андреевна (RU),Borisova Olga Vyacheslavovna (RU),Борисова Ольга Вячеславовна
申请号：
RU2020113187
公开号：
RU0002733170C1
申请日:
2020.03.27
申请国别(地区):
RU
年份:
2020
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to pediatric nephrology, and can be used for assessing the clinical effectiveness of children with nephrotic syndrome in remission. That is ensured by administering an immunosuppressive agent with an angiotensin-converting enzyme inhibitor 2.5 mg a day in the morning once； before the beginning of treatment, 6 and 12 months later, the patient is exposed to ultrasonic Doppler sonography of the renal vessels with evaluation of blood flow parameters, determined glomerular filtration rate by Schwartz formula； if in 6 months normalization of blood flow parameters is observed, absence of glomerular filtration decrease in comparison with data obtained before the treatment, then the treatment regimen is left unchanged for another 6 months, wherein in normalizing blood flow parameters 12 months after the beginning of treatment, the immunosuppressive preparation is canceled； if no blood flow parameters normalization is observed in 6 months, reducing the glomerular filtration rate as compared to the pre-treatment data, the therapy regimen is supplemented with the angiotensin II receptor blocker application in the nephroprotective dose, and the angiotensin-converting enzyme inhibitor dose is increased to 5 mg, and further evaluating clinical effectiveness 6 and 12 months after the treatment regimen is changed； in the absence of recurrences and positive dynamics of the results of test methods 12 months after the beginning of therapy, its effectiveness is considered to be high and the therapeutic regimen excludes the immunosuppressive preparation and the angiotensin receptor blocker if previously prescribed； with recurrence of the disease, no positive dynamics of the results of examination methods 12 months after the beginning of the therapy, the therapy regimen is preserved in full.EFFECT: method enables optimizing treatment of children by increasing renal survival.1 cl, 3 exИзобретение относится к медицине, а именно
